valproic acid has been researched along with isoproterenol in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hansson, E; Nilsson, M; Rönnbäck, L | 1 |
| Hellenbrecht, D; Kochen, W; Schneider, AL; von Klitzing, E; Wacarda, L | 1 |
| Bergh, N; Biber, B; Haney, M; Jern, S; Larsson, P; Omerovic, E; Saluveer, O; Svennerholm, K; Ulfhammer, E | 1 |
| Barchukov, VG; Kundashev, UK; Morozov, IS; Salenko, YA; Zurdinov, AZ | 1 |
1 review(s) available for valproic acid and isoproterenol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for valproic acid and isoproterenol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Receptor-coupled uptake of valproate in rat astroglial primary cultures.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Animals, Newborn; Astrocytes; Biological Transport; Cells, Cultured; Cerebral Cortex; Clonidine; Drug Interactions; Glutamates; Glutamic Acid; Isoproterenol; Kainic Acid; Ketanserin; Phenylephrine; Prazosin; Quinoxalines; Quisqualic Acid; Rats; Rats, Inbred Strains; Receptors, Neurotransmitter; Serotonin; Valproic Acid; Yohimbine | 1992 |
Experimental observations on peritoneal transport in rabbits.
Topics: Animals; Biological Transport; Creatinine; Disease Models, Animal; Dopamine; Fenoterol; Inulin; Isoproterenol; Kidney Failure, Chronic; Kinetics; Male; Nitroglycerin; Nitroprusside; Peritoneum; Proteins; Rabbits; Tissue Distribution; Valproic Acid | 1983 |
Histone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man.
Topics: Aged; Female; Forearm; Histone Deacetylase Inhibitors; Humans; Isoproterenol; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Tissue Plasminogen Activator; Valproic Acid | 2015 |
[EFFECT OF MEDIATOR-TYPE DRUGS ON HUMAN PSYCHOPHYSIOLOGICAL STATUS DURING MODEL OPERATOR ACTIVITY].
Topics: Adult; Anabasine; Attention; Belladonna Alkaloids; Benzodiazepines; Central Nervous System Stimulants; Dioxanes; Double-Blind Method; Haloperidol; Humans; Isoproterenol; Male; Propranolol; Psychophysiology; Sydnones; Task Performance and Analysis; Tranquilizing Agents; Valproic Acid; Yohimbine | 2016 |